Hi Monolith, I share your concerns at first, which is why I consulted a few people and read up on my own. I am not bio trained (so please take it with a pinch of salt and I may have made some mistakes) but from what i've read. I don't know about the other uses of the C1 platform, as I have been reading up mainly on glycoengineering and biologics drugs.
As you know FDA is pushing for non cho cells way of production for biologics drugs right now. For non cho cell ways of production, there are a few alternatives, but can be classified into Mammalian and non mammalian cells. Mammalian cells ways of production are not scalable, because they face similar problems as CHO cells, so that leaves us with non-mammalian cells means of production.
For non-mammalian cells means of production, the problems are that either you can't perform glcoengineering to make them more "human like" because their glycan structure are too different or they haven't been proven be able to be utilised on an industrial scale.
For C1, it has a very human like glycan structure (maybe even the most human like glycan structure amongst fungi and yeasts as stated below) and it also has a proof of concept in its scalability due to years of industrial use.
"CHO cells are most often used as production hosts when glycosylation is needed. Competing viral, yeast and bacterial systems that are evolutionarily distant from humans have glycosylation patterns that are largely incompatible with human use.
Dyadic is now performing glycoengineering work with C1 to knock in and knock out specific genes in the glycosylation pathways that are expected to produce human-like glycostructures. The glycoengineering work benefits from the fact that the glycoform structure of C1 more closely resembles the human glycan structure than that of other fungi and yeasts. Unlike most fungi and yeasts, C1 does not appear to have ‘high’ mannose (branched 30-50 mannose species), but rather has ‘oligo’ mannose and hybrid-type structure. None of the proteins analyzed to date contain the O-glycosylation structure commonly found in yeast and other fungi that is difficult to eliminate through glycoengineering steps.
Dyadic is focused on expressing proteins with specific glycoforms including G0, G1, G2, G0F, G1F and G2F which will improve the immunogenicity of vaccines via its glycoform structure. The company’s timeline anticipates achieving G1F and G2F structures by 2020, which will provide the necessary technology to manufacture glycosylated antibodies and other glycoproteins."
But please feel free to correct me if I am wrong in my understanding of this matter.
News 
Market Data 
Discover 
